

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Fernandez-Salas et al
Customer No.: 51957
Serial No.: Applied for
Conf. No.: Not known
Filed: Submitted herewith

Examiner: Not Known

Group Art Unit: Not Known

For: BOTULINUM TOXIN SCREENING
ASSAYS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant provides with regard to the above-identified patent application entitled BOTULINUM TOXIN SCREENING ASSAYS, one copy of documents of which he is aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

/Dean G. Stathakis/

Date: August 17, 2006

Dean G. Stathakis
Patent Agent
Registration Number 54,465

Please direct all inquiries and correspondence to:

Dean G. Stathakis
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92612
Tel: (714) 246-6521
Fax: (714) 246-4249

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17596(AP)	SERIAL NO.: Applied for
APPLICANT: FERNANDEZ-SALAS	TITLE: BOTULINUM TOXIN SCREENING ASSAY
FILING DATE: Submitted herewith	GROUP: Not known

U.S. PATENT DOCUMENTS

*EXAMINE R INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	5,750,365	5/12/1998	Chiu et al			
	AB	2004/0072270	4/15/2004	Ester Fernandez-Salas et al.			
	AC	5,925,528	7/20/1999	Chiu et al			
	AD	2004/0014024	1/22/2004	Thomassen-Wolf et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	AE	WO 02/102973	12/27/2002	PCT			
	AF	WO 02/102972	12/27/2002	PCT			
	AG	WO 2004/110487	12/23/ 2004	PCT			
	AH	WO 02/102854	12/27/2002	PCT			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AI	L-M. Sturla et al., FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells, 89(7) Br. J. Cancer 1276-1284 (2003)
	AJ	M. Kanai et al., Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein, 272(10) J. Biol. Chem. 6621-6628 (1997)
	AK	Janet E. Henderson et al., Expression of FGFR3 with the G380R achondroplasia mutation inhibits proliferation and maturation of CFK2 chondrocytic cells, 15(1) J. Bone Miner. Res. 155-165 (2000)
	AL	Noriko Yokosawa et al., Binding of Clostridium botulinum type C neurotoxin to different neuroblastoma cell lines, 57(1) Infect. Immun. 272-277 (1989)
	AM	Noriko Yokosawa et al., Binding of botulinum type CI, D and E neurotoxins to neuronal cell lines and synaptosomes, 29(2) Toxicon 261-264 (1991)
	AN	Tei-ichi Nishiki et al., Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes, 269(14) J. Biol. Chem. 10498-10503 (1994)
	AO	Hiroyuki Onose et al., Over-expression of fibroblast growth factor receptor 3 in a human thyroid carcinoma cell line results in overgrowth of the confluent cultures, 140(2) Eur. J. Endocrinol. 169-173 (1999)
	AP	Elizabeth E. Plowright et al., Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis, 95(3) Blood 992-998 (2000)

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17596(AP)	SERIAL NO.: Applied for
APPLICANT: FERNANDEZ-SALAS	TITLE: BOTULINUM TOXIN SCREENING ASSAY
FILING DATE: Submitted herewith	GROUP: Not known

		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)
	AQ	Yukako Fujinaga et al., Molecular characterization of binding subcomponents of Clostridium botulinum type C progenitor toxin for intestinal epithelial cells and erythrocytes, 150(Pt 5) Microbiology 1529-1538 (2004)
	AR	Atsushi Nishikawa et al., The receptor and transporter for internalization of Clostridium botulinum type C progenitor toxin into HT-29 cells, 319(2) Biochem. Biophys. Res. Commun. 327-333 (2004)
	AS	Erik A. Mijan and Eric G. Bremer, Regulation of Growth Factor Receptors by Gangliosides, 2002(160)Sci. STKE.RE15(2002)
	AT	Akio Shimizu et al, A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells, 276(14) J. Biol. Chem. 11031-11040 (2001)
	AU	C. J. Powers et al., Fibroblast growth factors, their receptors and signaling 7(3)Endocr. Relat. Cancer. 165-197 (2000)
	AV	Bernhard Reuss & Oliver von Bohlen und Halbach, Fibroblast growth factors and their receptors in the central nervous system, 313(2) Cell Tissue Res. 139-157 (2003)

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.